Mini Review
Accepted on 01 Oct 2025
METTL14 in Tumor Immunity: Epitranscriptomic Regulation and Therapeutic Potential
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1709742
Type at least 3 characters
8,633 articles
Review
Accepted on 01 Oct 2025
Senescent Immune Cells in the Tumor Microenvironment: Emerging Insights into Cancer Immunotherapy Resistance
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1656733
Original Research
Accepted on 01 Oct 2025
Reshaping CAR-T cells through overexpression of T cell factor 1 (TCF-1)
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1623869
Review
Published on 01 Oct 2025
Exosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applications
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1677088
- 172 views
Review
Published on 01 Oct 2025
Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1659011
- 203 views
Systematic Review
Published on 01 Oct 2025
Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1662455
- 464 views
Original Research
Published on 01 Oct 2025
AI-based non-invasive profiling of the tumor immune microenvironment using longitudinal CT radiomics predicts immunotherapy response in lung cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1664726
- 329 views
Original Research
Published on 01 Oct 2025
Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1683533
- 363 views
Brief Research Report
Published on 01 Oct 2025
Single-cell profiling deciphering cholesterol metabolism dysregulation in metastatic uveal melanoma and implicating SLC45A2 in its prognosis
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1660268
- 270 views
Review
Published on 01 Oct 2025
Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1661545
- 203 views
Original Research
Published on 01 Oct 2025
Development and validation of a novel sodium-overload related genes signature for prognostic prediction in breast cancer: integrating bioinformatics and experimental approaches
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1653903
- 329 views
Original Research
Published on 01 Oct 2025
Neoadjuvant outperforms adjuvant regimens in resectable advanced Chinese melanoma patients: lymph node preservation as a key immunological advantage
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1673308
- 837 views
Original Research
Published on 01 Oct 2025
Targeting the CCL28-STAT3-PLAC8 axis to suppress metastasis and remodel tumor microenvironment in colorectal cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1610540
- 124 views
Review
Published on 01 Oct 2025
Recapitulating the immune microenvironment in pediatric brain cancer: preclinical modeling strategies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1642668
- 308 views
Review
Accepted on 30 Sep 2025
Multiplex engineering and multifunction T cells for precise and effective immunotherapies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1680410
- 178 views
Systematic Review
Accepted on 30 Sep 2025
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1667793
- 169 views